Murine Model for Mantle Cell Lymphoma

The rate of Non-Hodgkin’s lymphoma (NHL) is rising in the United States with over 50,000 new cases diagnosed annually. Mantle cell lymphoma (MCL), a type of NHL, is a particularly aggressive cancer resistant to chemotherapy. Patients have a mean sur vival rate of 2.5 to 4 years. In order to develop effective treatments, a mouse model spontaneously developing MCL-like tumors is desperately needed. The IL-14/myc mice created here develop an aggressive lymphoma expressing MCL cell markers by the age of 4 months. The tumor spreads throughout the blood, bone marrow, spleen, liver, lymph nodes, gastrointestinal tract and lungs mimicking MCL in humans. This is the first and only model available offering phenotype and genotype characteristics m atching the blastoid variant of mantle cell lymphoma (BV-MCL).

Categories: Research Tool

Type of Offer: Licensing



« More Medical Patents

---